Ex­clu­sive: Trail­ing Karuna, Map­Light Ther­a­peu­tics aims to im­prove schiz­o­phre­nia, CNS drugs with $225M Se­ries C

Map­Light Ther­a­peu­tics has raised a $225 mil­lion round to en­ter Phase II clin­i­cal tri­als in schiz­o­phre­nia and Alzheimer’s dis­ease psy­chosis and run an on­go­ing mid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER